Oregon DEQ fines Drug Take-Back Program operator $648,500: See all of most-recent fines - statesmanjournal.com
Oregon DEQ has imposed a fine of $648,500 on a Drug Take-Back Program operator for non-compliance; this highlights the importance of adhering to regulatory standards.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All operators involved in drug take-back programs and related pharmaceutical waste management. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Significant fines have been levied for non-compliance with drug take-back regulations.
Who it affects
All operators involved in drug take-back programs and related pharmaceutical waste management.
What you must do
Review compliance with drug take-back program regulations to avoid similar penalties.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The FDA just cleared the way for drug importation. What now? - politico.com
- EPA names BD, Edwards and Medtronic on list of higher-risk sterilization facilities - MedTech Dive
- COVID-19 vaccines may be harder to get in Kentucky under new FDA guidelines. Here's why - The Courier-Journal
- Greek national indicted for selling counterfeit and unapproved prescription drugs to internet pharmacies and undercover agents - justice.gov
- Pfizer Kansas plant hit by FDA 483 with 8 repeat observations - bioprocessintl.com